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Background: Sarcopenia was recently recognized as an independent condition by an International Classiﬁca-
tion of Diseases, Tenth Revision, Clinical Modiﬁcation code, and is a frequently observed comorbidity in chronic
obstructive pulmonary disease (COPD). Muscle mass is primarily dictated by the balance between protein
degradation and synthesis, but their relative contribution to sarcopenia is unclear.
Objective: We aimed to assess potential differential molecular regulation of protein degradation
and synthesis, as well as myogenesis, in the skeletal muscle of COPD patients with and without
sarcopenia.
Methods: Muscle biopsies were obtained from the vastus lateralis muscle. Patients with COPD were
clustered based on sarcopenia deﬁned by low appendicular skeletal muscle mass index (nonsarcopenic
COPD, n ¼ 53; sarcopenic COPD, n ¼ 39), and compared with healthy nonsarcopenic controls (n ¼ 13).
The mRNA and protein expression of regulators and mediators of ubiquitin-proteasome system (UPS),
autophagy-lysosome system (autophagy), and protein synthesis were analyzed. Furthermore, mRNA
expression of myogenesis markers was assessed.
Results: UPS signaling was unaltered, whereas indices of UPS regulation (eg, FOXO1 protein; p-FOXO3/
FOXO3), autophagy signaling (eg, LC3BII/I; p-ULK1[Ser757]/ULK1), and protein synthesis signaling (eg,
AKT1; p-GSK3B/GSK3B; p-4E-BP1/4E-BP1) were increased in COPD. These alterations were even
more pronounced in COPD patients with sarcopenia (eg, FOXO1 protein; p-FOXO1/FOXO1; LC3BII/I;
p-ULK(Ser555); p-AKT1/AKT1; AKT1; p-4E-BP1). Furthermore, myogenic signaling (eg, MYOG) was
increased in COPD despite a concomitant increase of myostatin (MSTN) mRNA expression, with no
difference between sarcopenic and nonsarcopenic COPD patients.
Conclusion: Together with elevated myogenic signaling, the increase in muscle protein turnover signaling
in COPD, which is even more prominent in COPD patients with sarcopenia, reﬂects molecular alterations
associated with muscle repair and remodeling.
 2017 AMDA e The Society for Post-Acute and Long-Term Care Medicine..
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muscle mass, and was recently recognized as an independent condition
by an International Classiﬁcation of Diseases, Tenth Revision, Clinical
Modiﬁcation code.1 Apart from an age-associated decline in muscle
mass, sarcopenia also encompasses the loss of muscle mass due to
diseases such as chronic obstructive pulmonary disease (COPD).2 In
COPD patients, sarcopenia is a frequently observed comorbidity,
affecting exercise capacity,3,4 quality of life,3 and survival.5e7 Although
muscle mass maintenance is considered to be primarily dictated by the
balance between protein degradation and protein synthesis rates (ie,
protein turnover), their relative contribution to imbalanced protein
turnover during muscle mass loss remains unclear.
To provide a ﬁrst insight into the potential drivers of this imbalance
between muscle protein synthesis and breakdown in COPD patients,
several studies assessed the molecular regulation of skeletal muscle
protein turnover in COPD, and nearly all point to both increased
protein degradation signaling8e14 and increased protein synthesis
signaling.10,11,15 These ﬁndings are in accordance with the reported
increase in whole body protein turnover rate in COPD as assessed by
stable isotopes.16 It was previously suggested that increased protein
synthesis signaling in COPDmay serve to maintain muscle mass in the
presence of an elevated protein degradation rate.11 However, such a
compensatory mechanism to prevent muscle atrophy appears insuf-
ﬁcient, because the prevalence of sarcopenia in COPD patients is high
(ie, 12%e33%).17e19 Although there are some data available on protein
turnover signaling in sarcopenic COPD patients,8,9,11 these studies are
either limited in sample size or focus solely on either protein degra-
dation or protein synthesis signaling. Furthermore, the role of myo-
genesis in muscle mass maintenance is frequently overlooked or
incompletely assessed.
A comprehensive analysis of myogenic and protein turnover
regulation in COPD patients with and without sarcopenia would
provide further insight into the underlying skeletal muscle pathology,
potentially providing new targets for intervention. In the present
study, we therefore aimed to assess potential differential regulation of
protein degradation and synthesis, as well as myogenesis, through
analysis of an extensive panel of molecular regulators and mediators
of myogenic and protein turnover signaling in the skeletal muscle of
COPD patients with and without sarcopenia compared with healthy
controls.
Materials and Methods
Study Design and Participants
The skeletal muscle molecular proﬁles of patients from 2
prospective cohort studies were analyzed. The study performed in
Maastricht was registered at www.trialregister.nl as NTR1402, written
informed consent was obtained from all participants, and the study
was approved by the Maastricht University Medical Centreþ (Maas-
tricht, the Netherlands) ethical review board (08-2-059). The study
design was previously published.20 The study performed in Golnik
was registered at www.clinicaltrials.gov as NCT02550808, written
informed consent was obtained from all participants, and the study
was approved by the Slovenian National Medical Ethics Committee
(Ljubljana, Slovenia). The study design was previously published.21
Only data from baseline (ie, before pulmonary rehabilitation) mea-
surements were used in the current study. All included patients were
in a stable disease state, free from exacerbations in the 4 weeks before
start of the study protocol.
Participants were excluded from the current analysis if the muscle
biopsy or appendicular skeletal muscle mass index (ASMI) measure-
ment was missing. Sarcopenia was solely deﬁned according to cutoffs
for ASMI (<7.23 kg/m2 for men; <5.76 kg/m2 for women)22; see
Figure 1. One participant without COPD was classiﬁed as sarcopenicand was therefore excluded from the analyses, yielding a study
population of 13 healthy controls and 92 COPD patients.
Pulmonary and Physical Function
Spirometry was used to obtain forced expiratory volume in 1 sec-
ond (FEV1), forced vital capacity (FVC), and their ratio (FEV1/FVC) ac-
cording to the European Respiratory Society guidelines.23 Patients
were classiﬁed by disease severity based on Global Initiative for
Chronic Obstructive Lung Disease (GOLD) stage.24 Physical function
was assessed by peak load, determined by an incremental load cycling
test as previously described.25
Anthropometry and Body Composition
Bodymass index (BMI) was calculated as bodymass/height2 (kg/m2).
Whole body dual-energy x-ray absorptiometry (Hologic QDR Series
Explorer bone densitometer; Hologic Inc, Marlborough, MA) was used to
assess total and appendicular (ie, arms and legs) fat mass and fat-free
mass. Fat-Free Mass Index (FFMI) was calculated as fat-free mass/
height2 (kg/m2). ASMI was calculated as appendicular skeletal muscle
mass/height2 (kg/m2).
Muscle Biopsy and Analyses
Biopsies were obtained from the vastus lateralis muscle of the
dominant leg by needle biopsy, at least 20 hours after the last exercise
test. Muscle tissue was snap-frozen in liquid nitrogen, and stored
at 80C. Tissue processing and molecular analyses were performed
collectively.
Reverse TranscriptaseeQuantitative Polymerase Chain Reaction and
Western Blotting
Molecular analyses were performed in biopsies from all partici-
pants. After removal of technical outliers, which varied between
different analyses, the total sample size for protein and mRNA targets
included 10 to 13 controls, 50 to 53 nonsarcopenic patients with
COPD, and 38 to 39 sarcopenic COPD patients.
Details on the procedures and the exact sample size per analyzed
target are provided in the supplementary methods.
Statistics
Differences among nonsarcopenic patients with COPD, sarcopenic
patients with COPD, and controls were tested by 1-way analysis of
variance with Bonferroni post hoc comparisons in case of a signiﬁcant
group effect. Furthermore, differences between patients with COPD
and controls were tested using independent t test. Relevant results of
this comparison are presented in the ﬁgures. Analyses were per-
formed using SPSS Statistics (version 22.0; IBM Corp, Armonk, NY). A P
value less than .05 was considered statistically signiﬁcant.
Results
Participant Characteristics
Based on gender-speciﬁc cutoffs for ASMI,22 39 COPD patients (42%)
were sarcopenic, whereas 53 COPD patients (58%) and all control par-
ticipants were nonsarcopenic. Patient characteristics are presented in
Table 1. Although the sarcopenic COPD group contained slightly more
men, groups did not differ signiﬁcantly in sex distribution and age. BMI
was lower in sarcopenic than in nonsarcopenic COPD patients, but
controls did not differ from either COPD subgroup. Besides ASMI, FFMI
was lower in sarcopenic COPD patients than in nonsarcopenic COPD
44 study parcipants (Maastricht, NTR1402) 125 study parcipants (Golnik, NCT02550808)
29 parcipants with FEV1/FVC < 0.70 
(COPD)
15 parcipants with FEV1/FVC ≥ 0.70 
(Controls) 
125 parcipants with FEV1/FVC < 0.70
(COPD)
13 non-sarcopenic controls 39 sarcopenic COPD53 non-sarcopenic COPD
58 excluded because no muscle biopsy
4 excluded because missing ASMI
34 sarcopenic COPD29 non-sarcopenic
COPD
5 sarcopenic COPD24 non-sarcopenic
COPD
13 non-sarcopenic controls
1 excluded because no muscle biopsy
1 excluded because sarcopenic
Fig. 1. Flow chart of participant selection and clustering. Sarcopenia: ASMI <7.23 kg/m2 for men; <5.67 kg/m2 for women.22
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COPD patients compared with controls, and tended to be even further
decreased in sarcopenic COPD patients compared with nonsarcopenic
COPD patients. FEV1/FVC ratio and FEV1 (% predicted) were lower in
COPD patients than in controls, and FEV1 (% predicted) was even lower
in sarcopenic than in nonsarcopenic COPD patients. Correspondingly,
nonsarcopenic COPD patients most often had moderate (32%) to severe
(45%) COPD, whereas sarcopenic COPD patients most often had severe
(56%) to very severe (31%) COPD based on GOLD stage. Together, this
shows that lung function is more impaired in sarcopenic than in non-
sarcopenic COPD patients.
Protein Degradation Signaling
To assess potential differential regulation of skeletal muscle pro-
tein degradation signaling in COPD and sarcopenic COPD, markers ofTable 1
General Characteristics
Control,
n ¼ 13
COPD, No
Sarcopenia,
n ¼ 53
COPD,
Sarcopenia,
n ¼ 39
Overall
P Value
Demographics
Age, y 64.5  5.4 64.0  7.4 66.4  8.4 NS
Sex, % male 53.8 60.4 74.4 NS
Body composition
BMI, kg/cm2 24.8  3.4 26.7  4.0 22.9  2.8zzz <.001
ASMI, kg/cm2 7.48  1.01 7.42  1.01 6.03  0.85**/zzz <.001
Female 6.52  0.49 6.43  0.61 4.98  0.48**/zzz <.001
Male 8.31  0.37 8.06  0.64 6.39  0.61**/zzz <.001
FFMI, kg/cm2 17.9  1.9 18.0  2.5 15.9  2.4*/zzz <.001
Female 16.3  1.4 15.9  1.3 13.1  1.1**/zzz <.001
Male 19.2  1.0 19.5  2.0 16.8  1.9*/zzz <.001
Physical function
Peak load, Watt 190.3  62.8 73.4  24.4** 58.1  24.9**/y <.001
Female 136.0  6.3 65.5  19.2** 47.0  19.5**/z <.001
Male 236.9  48.9 78.1  26.1** 62.3  25.7** <.001
Lung function
FEV1, % predicted 113.5  12.9 48.6  18.3** 36.4  12.9**/zz <.001
FEV1/FVC, % 73.1  4.9 39.5  12.2** 34.5  9.8**/y <.001
GOLD, % <.05
1 6 0
2 32 13
3 45 56
4 17 31
Data presented as mean  SD. NS: P  .05, Signiﬁcant overall P values are indicated
in bold, Signiﬁcant post hoc comparisons after Bonferroni correction: *P < .05,
**P < .001, compared with control group; yP < .10, zP < .05, zzP < .01, zzzP < .001,
compared to nonsarcopenic COPD group.the 2 major proteolytic pathways were measured; that is, the
ubiquitin-proteasome system (UPS) and the autophagy-lysosome
system (autophagy), which are in part regulated by forkhead box O
(FOXO) transcription factors, including FOXO1 and FOXO3.
Progressively Increased FOXO Signaling in COPD and Sarcopenic
COPD
FOXO1 relative phosphorylation was unaltered in the skeletal
muscle of nonsarcopenic COPD patients, but tended to be lower in
sarcopenic COPD patients than in controls (Figure 2A). Remarkably,
FOXO1 protein levels were higher in both nonsarcopenic and sarco-
penic COPD patients than in controls, and were even further elevated
in sarcopenic COPD patients compared with nonsarcopenic COPD
patients (Figure 2C). This was paralleled by changes in FOXO1 mRNA
levels, which appeared higher in both nonsarcopenic and sarcopenic
COPD patients, but reached signiﬁcance only in sarcopenic COPD
patients compared with controls (Figure 2D). Absolute FOXO1 inhib-
itory phosphorylationwas concomitantly increased (Figure 2B), which
may reﬂect an adaptation to compensate for the elevated FOXO1
expression. No group differences were found in FOXO3 mRNA and
protein expression or absolute phosphorylation levels (Figure 2FeH);
however, relative FOXO3 phosphorylation was lower in both non-
sarcopenic and sarcopenic COPD patients than in controls (Figure 2E).
Unaltered UPS Signaling
In contrast to the apparent increase in FOXO activity, mRNA expres-
sion levels of the E3 ligases TRIM63 (tripartite motif containing 63
[MURF1]) and FBXO30 (F-box protein 30 [MUSA1]) were unaltered in the
skeletal muscle of nonsarcopenic and sarcopenic COPD patients
(Figure 3A, B). However, FBXO21 (F-box protein 21 [SMART]) mRNA
expression was higher in sarcopenic COPD patients than in controls
(Figure 3C), whereas FBXO32/MAFBX (F-box protein 32 [ATROGIN1])
mRNA expression tended to be lower in sarcopenic COPD patients than
in nonsarcopenic COPD patients (Figure 3D).
Progressively Increased Autophagy Signaling in COPD and
Sarcopenic COPD
Among the FOXO target genes are the autophagy-related genes
MAP1LC3B (LC3B [microtubule associated protein 1 light chain 3 beta]),
SQSTM1 (P62 [sequestosome 1]), and BECN1 (Beclin1).26,27 In line with
the unaltered MURF1 and MUSA1 mRNA levels, LC3B and P62 mRNA
expression remained unaltered (Figure 4D, F). BECN1 mRNA expres-
sion, however, was higher in COPD patients than in controls
(Figure 4H). Interestingly, LC3BI protein expression appeared higher in
both nonsarcopenic and sarcopenic COPD patients but reached sig-
niﬁcance only in sarcopenic COPD patients compared with controls,
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Fig. 2. FOXO regulation in COPD and sarcopenic COPD. (A) Relative FOXO1 phosphorylation at Tyr24. (B) Absolute FOXO1 phosphorylation at Tyr24. (C) FOXO1 protein expression.
(D) FOXO1 mRNA expression. (E) Relative FOXO3 phosphorylation at Tyr32. (F) Absolute FOXO3 phosphorylation at Tyr32. (G) FOXO3 protein expression. (H) FOXO3 mRNA
expression. Tyr, tyrosine. Values are means  SEM. *P < .05, **P < .01, ***P < .001, compared with control group or between indicated groups.
A.E.M. Kneppers et al. / JAMDA 18 (2017) 637.e1e637.e11637.e4whereas LC3BII levels were unaltered (Figure 4B, C). The resulting
lower LC3BII/I ratio in sarcopenic COPD patients than in controls
(Figure 4A) implies a change in autophagic ﬂux, although no change in
P62 protein expression was observed (Figure 4E). In line with the
altered LC3BII/I ratio, BECN1 protein expression seemed to be higher
in sarcopenic COPD patients (Figure 4G), but this did not reach sta-
tistical signiﬁcance.
An important juncture in the initiation of autophagy is activation of
unc-51 like autophagy activating kinase 1 (ULK1), which is regulated
through phosphorylation by the upstream kinases; mechanistic target
of rapamycin (MTOR) complex 1 (MTORC1) and AMPK. ULK1 relative
inhibitory phosphorylation (serine [Ser]757) was lower in both non-
sarcopenic and sarcopenic COPD patients than in controls (Figure 4I),
whereas relative ULK1 activating phosphorylation (Ser555) was unal-
tered (Figure 4K). Furthermore, absolute ULK1 Ser757 phosphorylation,
and ULK1 protein and mRNA expression were unaltered (Figure 4J, M,
N), whereas absolute ULK1 Ser555 phosphorylation tended to be higherA B C
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mRNA expression. Values are means  SEM. *P < .05, compared with control group or betin sarcopenic COPD patients than in controls and nonsarcopenic COPD
patients (Figure 4L).
Progressively Increased AKT/MTOR Signaling in COPD and
Sarcopenic COPD
Coordination of protein degradation and protein synthesis
signaling occurs via the PI3K/PKB (AKT serine/threonine kinase 1
[AKT1])/MTOR pathway. The relative phosphorylation of AKT1 was
lower in the skeletal muscle of both nonsarcopenic and sarcopenic
COPD patients than in controls, which tended to be more pronounced
in sarcopenic COPD patients compared with nonsarcopenic COPD
patients (Figure 5A). This reduced relative AKT1 phosphorylation did
not result from a change in absolute AKT1 phosphorylation levels
(Figure 5B) but from a higher AKT1 protein expression in non-
sarcopenic and sarcopenic COPD patients than in controls, and in
sarcopenic COPD patients compared with nonsarcopenic COPD pa-
tients (Figure 5C). Despite the change in AKT1 regulation, MTORD
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A.E.M. Kneppers et al. / JAMDA 18 (2017) 637.e1e637.e11 637.e5phosphorylation (Figure 5D, E) and expression (Figure 5F) were
unaltered. However, relative and absolute phosphorylation of
the downstream AKT1 target glycogen synthase kinase 3 beta
(GSK3B) were higher in sarcopenic COPD patients than in controls
(Figure 5GeI), suggesting increased AKT1 activity.
Progressively Increased Protein Synthesis Signaling in COPD and
Sarcopenic COPD
Although the MTORC1 downstream effector ribosomal protein S6
(RPS6) displayed unaltered relative phosphorylation (Figure 6A), both
RPS6 protein expression and absolute phosphorylationwere higher in
COPD patients than in controls (Figure 6B, C). Furthermore, both
relative and absolute phosphorylation of the translation repressor
EIF4EBP1 (4E-BP1 [eukaryotic translation initiation factor 4E binding
protein 1]) were higher in sarcopenic COPD patients than in controls
(Figure 6DeF).Increased Myogenic Signaling in COPD
Increased protein degradation and protein synthesis signaling in
COPD and sarcopenic COPD suggest an increase in protein turnover. A
similar pattern of molecular alterations has been observed during
muscle remodeling after exercise.28 We therefore asked if myogenesis, a
process that is also implicated in muscle repair and remodeling, is
increased in COPD and sarcopenic COPD patients as well. To this end,
markers of satellite cell function were evaluated. The mRNA expression
levels of the satellite cell marker paired box 7 (PAX7) and the prolifera-
tion markers proliferating cell nuclear antigen (PCNA) and cyclin D1
(CCND1) were unaltered in nonsarcopenic and sarcopenic COPD patients
(Figure 7AeC). Furthermore, the mRNA expression of myogenic factor 5
(MYF5) was unaltered (Figure 7D). In contrast, myogenic differentiation 1
(MYOD1) and myogenin (MYOG) mRNA expression was higher in COPD
patients than in controls (Figure 7E, F), and CDH15 (cadherin 15
[M-cadherin]) mRNA expression showed a similar trend (Figure 7G). This
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Fig. 5. AKT/MTOR signaling in COPD and sarcopenic COPD. (A) Relative AKT phosphorylation at Ser473. (B) Absolute AKT phosphorylation at Ser473. (C) AKT protein expression. (D)
Relative MTOR phosphorylation at Ser2448. (E) Absolute MTOR phosphorylation at Ser2448. (F) MTOR protein expression. (G) Relative GSK3B phosphorylation at Ser9. (H) Absolute
GSK3B phosphorylation at Ser9. (I) GSK3B protein expression. Tyr, tyrosine. Values are means  SEM. *P < .05, compared with control group or between indicated groups.
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By assessing a comprehensive panel of molecular regulators of
muscle protein turnover, we demonstrate that both protein degrada-
tion and synthesis signaling are increased in the skeletal muscles of
COPD patients, and extend previous ﬁndings by showing that these
alterations are even more prominent in sarcopenic COPD patients.
Furthermore, we show that myogenic differentiation signaling is
increased in COPD, which is maintained, but not aggravated in sar-
copenic COPD.
Several studies have addressed protein degradation and/or protein
synthesis signaling in COPD or sarcopenic COPD.8e14,29,30 However, due
to differences in characteristics of the control groups, differences in
disease severity of the COPD populations, and differences in body
composition phenotyping, these studies cannot be directly compared or
combined to extrapolate a conclusion on protein turnover regulation in
COPD-related sarcopenia. In the present study, we therefore measured
an extensive panel of molecularmarkers in skeletal muscle biopsies of a
large, well-phenotyped COPD cohort to assess potential differential
regulation of protein degradation and synthesis in the skeletal muscle
of COPD patients with and without sarcopenia, and hint toward its
potential implications for the level of protein turnover. Although we
recognize that muscle protein degradation and synthesis rates were not
measured in this study, given that this is a general limitation of many
studies in humans, coordination between signaling and rates of turn-
over can be extrapolated from previous studies.31
Previous studies suggested increased FOXO signaling in the skel-
etal muscle of COPD patients and sarcopenic COPD patients.11,29
Correspondingly, we ﬁnd lower relative FOXO1 and FOXO3 inhibi-
tory phosphorylation in COPD patients, implicating increased FOXO
transcriptional activity. In line, the mRNA expression of the FOXO
target SMART is higher in sarcopenic COPD patients than in controls.
However, although previous reports showed increased ATROGIN18,9,13
and MURF111,29 expression in COPD and sarcopenic COPD, the present
study shows no increase in the mRNA expression of ATROGIN1,MURF1,
or MUSA1. In agreement with the study of Natanek et al,30 ATROGIN1A B C
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Fig. 7. mRNA expression of myogenic markers in COPD and sarcopenic COPD. (A) PAX7 m
mRNA expression. (E) MYOD1 mRNA expression. (F) MYOG mRNA expression. (G) M-cadhe
***P < .001, compared with control group.mRNA expression even tends to be lower in sarcopenic COPD patients
than in nonsarcopenic COPD patients. Although the current data seem
in disagreement with some of the previous literature, we and others
have suggested that the increased expression of E3 ligases might be a
feature of acute catabolic events rather than chronic muscle
wasting,30,32,33 the latter of which was studied in this cohort. We
speculate that a recurring rise in UPS activity during repeated disease
exacerbations results in an increased capacity for UPS induction,
rendering the skeletal muscle more susceptible to catabolic trig-
gers.34,35 The higher FOXO1 protein and mRNA expression levels in
muscle tissue of COPD patients and sarcopenic COPD patients may
reﬂect such an increase in UPS inductive capacity. In this regard, the
elevated absolute FOXO1 phosphorylation level may serve as a
compensatory inhibition of (excess) protein degradation signaling in
the stable disease phase.
In line with unaltered E3 ligase expression, the mRNA expression of
autophagy-related FOXO target genes, LC3B and P62, is unchanged in
COPD and sarcopenic COPD patients. Nonetheless, the higher BECN1
mRNA expression level in COPD patients than in controls, and the
apparent elevation in BECN1 protein expression in sarcopenic
compared with nonsarcopenic COPD patients hint toward increased
autophagy in COPD and sarcopenic COPD. It was previously shown that
the number of autophagosomes is higher in the skeletalmuscle of COPD
patients and muscle-wasted COPD patients than in controls.14,29
Although autophagic ﬂux cannot be measured in vivo in humans, the
lower LC3BII/I ratio in sarcopenic COPD patients compared with con-
trols indicates that the level of autophagic ﬂux is altered. The relative
inhibitory phosphorylation (Ser757) of ULK1, an important juncture in
autophagy initiation, is lower in COPD patients than in controls.
Furthermore, the absolute Ser555 phosphorylation level tends to be
higher in sarcopenic COPD patients than in controls or nonsarcopenic
COPD patients. Together, this suggests that in the skeletal muscle of
COPD patients, and even more prominent in sarcopenic COPD patients,
autophagy is increased.
Higher absolute FOXO1 phosphorylation levels in COPD and sar-
copenic COPD patients can result from increased AKT1 activity.D
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Fig. 8. Schematic presentation of sarcopenia-related molecular alterations in COPD.
COPD-related factors leading to muscle damage and remodeling may drive the increase
in myogenic and protein turnover signaling in COPD, as well as the even further
increased protein turnover signaling in sarcopenic COPD, which may impair recovery
after an exacerbation, leading to a progressive loss of muscle mass and function. Black
text represents the regulation of indicated processes as measured in the current study,
whereas gray text represents their associations and implications from previous liter-
ature. *Puig-Vilanova et al.29
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activity in COPD and sarcopenic COPD based on the relative AKT1
phosphorylation.11,14 In line with this, we ﬁnd lower relative
AKT1 phosphorylation in nonsarcopenic COPD patients than in
controls, and a trend toward a further decrease in sarcopenic COPD
patients compared with nonsarcopenic COPD patients. Notably, the
lower AKT1 relative phosphorylation is not reﬂective of altered ab-
solute AKT1 phosphorylation, but rather of higher AKT1 protein
expression. Moreover, phosphorylation levels of other downstream
targets of AKT1 (ie, GSK3B, RPS6, 4E-BP1) suggest increased AKT1
activity. This stresses the need to not merely predict the enzymatic
activity of phosphoproteins based on their relative phosphorylation
state, but to also consider alterations in total protein abundance.
Indeed, although the relative RPS6 phosphorylation remains unal-
tered, both the expression and activating phosphorylation level of
RPS6 are higher in COPD patients than in controls, which is suggestive
of increased mRNA translation capacity. Furthermore, the absolute
inhibitory phosphorylation level of the negative regulators of trans-
lation initiation, GSK3B and 4E-BP1, is higher in sarcopenic COPD
patients than in controls, implicating increased mRNA translation
initiation. Together, these results show that the stimulatory signaling
and capacity for protein synthesis is increased in the skeletal muscle of
COPD patients in a stable disease state, particularly in those with
sarcopenia.
Alterations in protein turnover are not necessarily accompanied by
changes in muscle mass, and may serve several physiological pro-
cesses, including muscle remodeling.28 For example, recovery from
muscle injury caused by eccentric exercise is accompanied by an in-
crease in protein synthesis signaling.36 Furthermore, a recent study
showed an induction of autophagy during recovery from muscle
injury and suggested a role for autophagy in muscle regeneration.37 In
the present study, muscle biopsies were taken at a basal state.
Therefore, the increased autophagy and protein synthesis signaling
suggest ongoing skeletal muscle remodeling in COPD and sarcopenic
COPD patients, which may relate to muscle phenotypic alterations
or damage repair. Indeed, previous studies showed damage of
sarcomeres in the skeletal muscle of cachectic COPD patients.29
Furthermore, recovery from muscle damaging eccentric exercise is
accompanied by an increase in skeletal muscle satellite cell content,38
which is indicative of myogenesis. Thèriault et al39 reported unaltered
satellite cell numbers in COPD patients with and without muscle
wasting, whereas the number of central nuclei was higher in COPD
patients with preserved muscle mass. Based on myogenic regulatory
factor (MRF) protein expression, they suggested that satellite cells in
COPD are under a sustained proliferative state. The current study,
however, shows no change in themRNA expression of PAX7, PCNA, and
CCND1, suggesting no alteration in satellite cell numbers or prolifer-
ation in muscle of COPD patients. Furthermore, MYF5 mRNA expres-
sion is unaltered, whereas the mRNA expression levels of M-cadherin
and the MRFs,MYOD1 andMYOG, are higher in COPD patients than in
controls. Together, this points toward increased myogenic differenti-
ation signaling in COPD, which is maintained, but not aggravated, in
sarcopenic COPD.
Strikingly, but in line with previous research,13 MSTN mRNA
expression is higher in the skeletal muscle of COPD patients than in
controls. MSTN is commonly known as a negative regulator of protein
synthesis and myogenesis.40 However, when considering the seem-
ingly contradictory increase in expression of both MSTN and MRFs in
COPD, it should be taken into account that the effect of MSTN is
context dependent.41,42 In vitro data showed that MSTN negatively
affects myoblast proliferation and myogenic differentiation,43,44 and
in vivo MSTN deﬁciency elevates satellite cell numbers due to
increased self-renewal.41 As such, it seems obvious that proliferation is
inhibited by MSTN. However, the inhibitory effect of MSTN on cell
cycle progression,41 often interpreted as detrimental for myogenesis,may actually facilitate terminal differentiation.42,45 The higher MSTN
and MRF mRNA expression in COPD may therefore be a physiological
response to promote terminal differentiation as part of an increased
demand for myonuclear accretion. Importantly, several studies sug-
gest that temporal expression of MSTN controls the balance between
proliferation and differentiation of satellite cells.41,46,47 A sustained
elevation of MSTN expression may therefore impair satellite cell
activation and negatively regulate self-renewal,41 eventually resulting
in satellite cell senescence and depletion of the satellite cell pool.42,48
In conclusion, these results conﬁrm increased protein degradation
and synthesis signaling in the skeletal muscle of COPD patients
compared with controls and show further stimulation of these pro-
cesses in sarcopenic COPD patients compared with nonsarcopenic
COPD patients. Together with the increase in myogenic signaling, this
mirrors molecular alterations observed during muscle repair and
remodeling (Figure 8).Implications and Future Perspectives
Factors implicated in COPD-related sarcopenia, including oxidative
stress and inﬂammation,32 can result from and cause cellular dam-
age,49,50 andmay drive repair and remodeling-likemolecular alterations.
Although these molecular alterations are likely necessary to facilitate
repair of myoﬁber damage, a sustained increase in protein turnover
regulation elevates the energetic costs of protein metabolism,51 whereas
a sustained increase in myogenic signaling could result in satellite cell
A.E.M. Kneppers et al. / JAMDA 18 (2017) 637.e1e637.e11 637.e9depletion. This may not affect muscle mass substantially in a stable
disease state, but it remains elusive to what extent this affects the co-
ordination between anabolic signaling and the anabolic response
required for muscle mass recovery after an exacerbation.
Future studies should therefore address the underlying mecha-
nisms and pathophysiological relevance of repair and remodeling in
the context of physiological responses to anabolic and catabolic
stimuli in COPD patients, to elucidate the role of altered protein
turnover and myogenic regulation in the development and treatment
of COPD-related sarcopenia.References
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Reverse TranscriptaseeQuantitative Polymerase Chain Reaction
Tissue was homogenized (Mini-BeadBeater; Biospec Products, Bar-
tlesville, OK) in the presence of TRI-reagent (Sigma-Aldrich, St Louis,
MO), and RNA was isolated by TRI-reagent/chloroform extraction and
subsequently precipitated from the aqueous phase using glycogen-
containing isopropanol. RNA was reconstituted in 30 mL RNA storage
solution (AM7001; Ambion, Austin, TX) and stored at 80C. RNA con-
centrations were measured spectrophotometrically using a Nanodrop
UV-Vis spectrophotometer (ND-1000;ThermoScientiﬁc,Waltham,MA).
A total of 400 ng RNA was diluted in nuclease-free H2O and reverse
transcribed to cDNAusing theTetro cDNAsynthesis kit (Bioline, Taunton,
MA) according to the manufacturer’s instructions. Quantitative poly-
merase chain reaction (qPCR) primerswere designed based on Ensembl
transcript sequences and ordered fromSigmaGenosys (Zwijndrecht, the
Netherlands), with primer details shown in Table E1. qPCR reactions
contained Sensimix SYBR and ROX (GC Biotech, Alphen aan den Rijn, the
Netherlands) and primermix, andwere run in a 384-well white opaque
plate (Roche, Basel, Switzerland) on a LightCycler 480 system (Roche).
Melting curves were analyzed to verify speciﬁcity of the ampliﬁcation,
and relative quantity of the targets was assessed by LinRegPCR software
(v2014.8; bioinfo@amc.uva.nl).1 Three reference genes (RPLP0, B2M, and
PPIA)were used to calculate aGeNormcorrection factor,whichwasused
to normalize expression levels of the target genes.
Western Blot
Tissuewas homogenized in 600 mL immunoprecipitation lysis buffer
(50mMTris,150mMNaCl,10% glycerol, 0.5% Nonidet P40, protease and
phosphatase inhibitors [Roche]) with a Micro Tissue Homogenizer
(Kimble-Kontes, Vineland, NJ). After homogenization, samples were
incubated on a tube rotator at 4C for 30 minutes and centrifuged at
14,000g at 4C for 30 minutes. The supernatant was stored at 80C
until analysis. Total protein concentration was determined using a BCA
Protein Assay kit (Pierce Biotechnology, Waltham, MA) according to themanufacturer’s instructions. For Western blot analyses, 4 Laemmli
sample buffer (0.25 M Tris-HCL pH 6.8, 8% [wt/vol] sodium dodecyl
sulfate, 40% [vol/vol] glycerol, 0.4 M dithiothreitol, and 0.02% [wt/vol]
Bromophenol Blue) was added and samples were heated to 100C for
5 minutes; 10 mg proteinwas separated on a Criterion XT Precast 4-12%
Bis-Tris gel (Bio-Rad, Hercules, CA) in XTMOPS running buffer (Bio-Rad)
by gel electrophoresis. Proteins were transferred to a nitrocellulose
membrane (Bio-Rad) by electroblotting at 100 V for 60 minutes in
transfer buffer (25 mM Tris, 192 mM glycine, 20% [vol/vol] methanol).
For total protein detection, the membrane was stained with Pon-
ceauS solution (0.2% PonceauS in 1% acetic acid; Sigma-Aldrich Chemie,
Taufkirchen, Germany) and imaged using the Amersham imager
600RGB (GEHealthcare, Pittsburgh, PA). Themembranewas blocked for
1 hour at room temperature (RT) in Tris-buffered saline with Tween20
(TBST; 20 mM Tris, 137 mM NaCl, 0.1% [vol/vol] Tween20, pH 7.6)
containing 3% (wt/vol) nonfat dry milk (Campina, Eindhoven, the
Netherlands). The membranes were washed in TBST, followed by
overnight incubation at 4Cwith primary antibody diluted in TBSTwith
3% bovine serum albumin or nonfat dry milk (Table E2). Membranes
were incubated with a peroxidase-conjugated secondary antibody
solution (#PI-1000, diluted 1:10,000 in blocking solution; Vector
Laboratories, Burlingame, CA) for 1 hour at RT, and targets were visu-
alized by chemiluminescence using Supersignal West PICO or FEMTO
Chemiluminescent Substrate (Pierce Biotechnology) according to the
manufacturer’s instructions, and detected using the Amersham imager
600RGB. Signals were quantiﬁed with Image Quant software (Amer-
sham). For analyses, samples from controls and patients with chronic
obstructive pulmonary disease (COPD) were randomly distributed
within and between blots, and reference samples were loaded onto all
blots to correct for between-blot variation. Protein expression and
phosphorylation levels were corrected for total protein content, and
presented as a fold change compared with the control group.
Table E2
Primary Antibody List
Target n* Supplier Product No.
FOXO1 12/52/38 Cell Signaling 2880
FOXO3 12/52/38 Cell Signaling 2497
FOXO1 (Tyr24)/FOXO3(Tyr32) 11/52/38 Cell Signaling 9464
LC3B 12/52/38 Cell Signaling 2775
P62 12/53/38 Cell Signaling 5114
BECN1 12/53/38 Novus Biologicals NB110-87318SS
ULK1 12/53/38 Cell Signaling 8054
ULK1(Ser757) 12/53/38 Cell Signaling 6888
ULK1(Ser555) 12/53/38 Cell Signaling 5869
AKT1 12/53/39 Cell Signaling 2920
AKT(Ser473) 12/53/39 Cell Signaling 4060
MTOR 11/53/39 Cell Signaling 2983
MTOR(Ser2448) 11/53/39 Cell Signaling 2971
GSK3B 12/53/39 Cell Signaling 12456
GSK3B(Ser9) 12/53/39 Cell Signaling 9336
4E-BP1 12/53/39 Cell Signaling 9452
4E-BP1(Ser65) 12/53/39 Cell Signaling 9451
RPS6 10/53/39 Cell Signaling 2317
RPS6(Ser235/236) 10/53/39 Cell Signaling 4858
AKT1, AKT serine/threonine kinase 1; BECN1, Beclin1; FOXO1, forkhead box O1;
FOXO3, forkhead box O3; GSK3B, glycogen synthase kinase 3 beta; LC3B,
microtubule-associated protein 1 light chain 3 beta; MTOR, mechanistic target of
rapamycin; P62, sequestosome 1; RPS6, ribosomal protein S6; Ser, Serine; Tyr,
tyrosine; ULK1, unc-51 like autophagy activating kinase 1; 4E-BP1, eukaryotic
translation initiation factor 4E binding protein 1.
*Sample size (controls/nonsarcopenic COPD patients/sarcopenic COPD patients).
Table E1
qPCR Primer Sequences of Genes of Interest and Reference Genes
Target n* Source Forward Reverse
FOXO1 13/51/38 ENSG00000150907 CCTGGACATGCTCAGCAGACATC TTGGGTCAGGCGGTTCATACC
FOXO3 13/51/38 ENSG00000118689 CACTGGTGCTAAGCAGGCCTCAT ATGGCGTGGGATTCACAAAGGT
MURF1 13/51/38 ENSG00000158022 GCGAGGTGGCCCCATT GATGGTCTGCACACGGTCATT
MUSA1 13/50/38 ENSG00000118496 AGTACTCCTGACAGCAGCAG CATTGACACAGAAGTCAATCACTC
SMART 13/50/38 ENSG00000135108 AATTAATCTGAAAGGCACTGTGTC TGAAGACAGAATGTCACAAACTG
ATROGIN1 13/51/38 ENSG00000156804 GAAGAAACTCTGCCAGTACCACTTC CCCTTTGTCTGACAGAATTAATCG
LC3B 13/51/38 ENSG00000140941 ACCATGCCGTCGGAGAAGAC TCTCGAATAAGTCGGACATCTTCTACTCT
P62 13/51/38 ENSG00000161011 GGTGCACCCCAATGTGATCT CGCAGACGCTACACAAGTCG
BECN1 13/51/38 ENSG00000126581 AATGCAACCTTCCACATCTGGC CCCAGCCTGAAGTTATTGATTGTGC
ULK1 13/50/38 ENSG00000177169 TGCCCGGTGTCCTGGTCCTC CAGGGGCAGCAGTTGAGGCG
PAX7 13/50/38 ENSG00000009709 TACAGCACCACCGGCTACAGCGTG CTGGCCGTACTGGCCGTACTGATAG
PCNA 13/50/38 ENSG00000132646 TCTGCAAGTGGAGAACTTGGAA GAAGTTCAGGTACCTCAGTGCAA
CCND1 13/50/38 ENSG00000110092 ACCGCCTCACACGCTTCCTCT GCCTGGCGCAGGCTTGACTC
MYF5 13/50/38 ENSG00000111049 TGCCCGAATGTAACAGTCCT AGCAATCCAAGCTGGATAAGG
MYOD1 13/51/38 ENSG00000129152 CAATCCAAACCAGCGGTTGC CCTCGATATAGCGGATGGCGT
MYOG 13/51/38 ENSG00000122180 TCAGCGCCAACCCAGG GGTGAGGGAGTGCAGGTTGT
M-cadherin 13/50/38 ENSG00000129910 CCTGGACATCGCCGACTTCA TGGGGTCACTATCTGCAGCC
MSTN 13/51/38 ENSG00000138379 AACCTTCCCAGGACCAGGAGAA TGTCTGTTACCTTGACCTCTAAAAACGG
RPLP0 13/51/38 ENSG00000089157 TCTACAACCCTGAAGTGCTTGATATC GCAGACAGACACTGGCAACATT
B2M 13/51/38 ENSG00000196262 CATCTGCACTGCCAAGACTGA TTCATGCCTTCTTTCACTTTGC
PPIA 13/51/38 ENSG00000166710 CTGTGCTCGCGCTACTCTCTCTT TGAGTAAACCTGAATCTTTGGAGTACGC
ATROGIN1 (FBXO32/MAFBX), F-box protein 32; B2M, beta-2-microglobulin; BECN1, Beclin1; CCND1, cyclin D1; FOXO1, forkhead box O1; FOXO3, forkhead box O3; LC3B
(MAP1LC3B), microtubule-associated protein 1 light chain 3 beta; M-cadherin (CDH15), cadherin 15; MSTN, myostatin; MURF1 (TRIM63), tripartite motif containing 63;
MUSA1 (FBXO30), F-box protein 30; MYF5, myogenic factor 5; MYOD1, myogenic differentiation 1; MYOG, myogenin; P62 (SQSTM1), sequestosome 1; PAX7, paired box 7;
PCNA, proliferating cell nuclear antigen; PPIA, peptidylprolyl isomerase A; RPLP0, ribosomal protein lateral stalk subunit P0; SMART (FBXO21), F-box protein 21; ULK1, unc-51
like autophagy activating kinase 1.
*Sample size (controls/nonsarcopenic patients with COPD patients/sarcopenic patients with COPD).
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